An outbreak of respiratory illness that began in Mexico in late March 2009 has subsequently been attributed to a novel swine-origin influenza A (H1N1) virus (H1N1-2009).[@CR1] As of September 6, 2009, over 277,600 laboratory-confirmed cases were reported in over 100 countries.[@CR2] In Canada, since the first laboratory-confirmed cases of H1N1-2009 were identified in a group of students from Nova Scotia who had travelled to Mexico in early April 200[@CR3],[@CR9] there have been over 10,000 laboratory-confirmed cases of H1N1-2009, including over 1,000 patients who were hospitalized and 74 patients who have died.[@CR4],[@CR5] Canada has the highest rate of confirmed cases of H1N1-2009 with a disproportionate number of young patients, females, Aboriginals, and patients who do not have major comorbidities affected.[@CR6]

Most patients diagnosed with H1N1-2009 virus have had a self-limited respiratory illness, have exhibited symptoms similar to those of seasonal influenza, including cough, fever, sore throat, malaise and headache, and have recovered without complication.[@CR7] However, approximately 5-9% of these patients in the United States[@CR8],[@CR9] and 11% in Canada[@CR5] required hospitalization. Further, 20-36% of hospitalized patients were admitted to the intensive care unit (ICU). Over 80% of patients admitted to the ICU required mechanical ventilation and 17-40% died.[@CR10] Infection with H1N1-2009 can result in rapidly progressive respiratory failure, acute respiratory distress syndrome (ARDS), and death.[@CR11]

Mechanical ventilation is usually necessary to support gas exchange in patients with ARDS, although mechanical ventilation itself can be associated with lung injury. Despite attempts to optimize ventilator settings,[@CR12] hypoxemia or hypercapnia refractory to conventional mechanical ventilation may persist in a small subset of patients, and these patients may be treated with extracorporeal lung support (ECLS). Extracorporeal membrane oxygenation (ECMO) is a technology of facilitating gas exchange over a microporous membrane by pumping the patient's blood through an extracorporeal circuit. Recently, a pumpless circuit was developed (interventional lung assist, iLA) that is specifically effective for carbon dioxide removal.[@CR13] So far, ECLS has been provided in specialized centres as an alternative therapy for patients who have not responded to conventional treatment. This report describes the epidemiologic characteristics, clinical features, treatment, and outcomes of a multicentre cohort of adult and pediatric Canadian ICU patients who had severe respiratory failure due to H1N1-2009 virus and were treated with ECLS.

Methods {#Sec1}
=======

In response to an outbreak of H1N1-2009 infection in Mexico, members of the Canadian Critical Care Trials Group (CCCTG) developed a case report form and designed a multicentre observational study of critically ill patients who were infected with this virus. Data were collected retrospectively or prospectively on all patients who had H1N1-2009-related critical illness from April 2009 to August 2009. On April 30, 2009, research ethics board approval was granted by Sunnybrook Health Sciences Centre as the central coordinating centre and by each participating local research ethics board. The need for *a priori* informed consent was waived due to the non-interventional study design. The results of the entire cohort were recently published.[@CR10] An additional form was developed and disseminated to allow collection of ECLS-specific data. Herein we present a detailed examination of patients who were supported with ECLS. The use and indications for ECLS were left to the treating physician. For study purposes, indications for ECLS were grouped into broad categories, i.e., hypoxemia, hypercarbia, impossible to ventilate, other, and the worst physiologic data preceding initiation of ECLS were recorded.

Eligible patients included all adult and pediatric critically ill patients, as previously defined,[@CR10] who were admitted to participating ICUs in Canada and had suspected, probable, or confirmed H1N1-2009 infection.[@CR14],[@CR15] Eligibility criteria were confirmed and data were recorded by research coordinators or site investigators at each centre. Severity of illness was assessed in adults and children using the Acute Physiology and Chronic Health Evaluation (APACHE) II and the Pediatric Risk of Mortality (PRISM) III score,[@CR16],[@CR17] respectively. We recorded co-morbidities and *a priori* defined major co-morbidities as the presence of one or more of the following chronic medical conditions: congestive heart failure; cerebrovascular, neoplastic, chronic liver, or renal diseases; and use of immunosuppressant medications.[@CR18] Data were submitted to the coordinating centre and checked for errors by manual inspection and electronic range limits. Descriptive statistics included frequency analysis (percentages) for categorical variables and means (standard deviation \[SD\]) or medians (interquartile range \[IQR\]) for continuous variables. Analyses were conducted using SAS^®^ version 9.1 (SAS Institute, Cary, NC, USA).

Results {#Sec2}
=======

Characteristics of study patients {#Sec3}
---------------------------------

As previously reported,[@CR10] from April 2009 to August 2009, 168 critically ill patients were admitted to 34 study ICUs in Canada due to confirmed H1N1-2009 infection. The average age was 32 yr and 67.3% were female (Table [1](#Tab1){ref-type="table"}). Six of these patients were unresponsive to conventional therapy and were treated with ECLS. Although there were no standard inclusion/exclusion criteria, all ECLS programs were heavily influenced by the criteria outlined in the Conventional Ventilation or ECMO for Severe Adult Respiratory Failure (CESAR) trial,[@CR19] with hypoxemia (P/F ratio \< 100 on F~[i]{.smallcaps}~O~2~ = 1.0) being the primary indication for ECLS in our series. These patients were profoundly hypoxemic (mean PaO~2~/F~[i]{.smallcaps}~O~2~ 61 mmHg) and hypercapneic (mean PaCO~2~ 70 mmHg) one hour before the start of ECLS. Three patients were treated with high frequency oscillation ventilation (HFOV); all received inhaled nitric oxide during their ICU stay, and two had hemodynamic instability requiring intravenous inotropic medication. Two patients had a cardiac arrest before initiation of ECLS. Table [2](#Tab2){ref-type="table"} outlines the ECLS patient characteristics.Table 1Clinical Characteristics of H1N1-2009 patients who received ECLS as compared to the entire cohort of 168 patients as previously reported[@CR10]Patient Characteristics at BaselineECLS PatientsAll Patients[@CR10]Confirmed cases, n6168Age (years)22 (15.5)32.3 (21.4)Sex (female), n (%)5 (83%)113 (67.3%)BMI (kg/m^2^)32.6 (7.4)34.6 (11)First Nations/Inuit/Aboriginal, n (%)2 (33)43 (25.6)APACHE II Score25 (3)19.7 (8.7)*Time Course of Illness (days)*From Symptoms to Hospital Admission6 \[2-6\]4 \[2-7\]From Hospital to ICU Admission0.5 \[0-2.5\]1 \[0-2\]From Hospital Admission to ECLS5 \[2.5-8.3\]-From ICU Admission to ECLS4.5 \[3.3-8\]-*Oxygenation at ICU Admission*Set PEEP (cm H~2~O)15 (9)9.8 (4.0)FiO~2~0.85 (0.20)0.74 (0.26)PaO~2~ (mm Hg)69 (12)95 (57)PaO~2~/FiO~2~ (mm Hg)83 \[11\]147 \[128\]*Organ Dysfunction at ICU Admission*Creatinine (mmol/L)65 \[64-76\]65 \[44-102\]AST (units/L)86 \[86-153\]64 \[37-126\]White Blood Cells (total/mm^3^)6.8 (6.5)9.4 (10.0)Platelets (x10^3^/ml)115 (129)189 (87)Bilirubin (mg/dL)22 \[4-23\]7 \[4-14\]Creatine Kinase (units/L)361 \[250-641\]243 \[99-922\]*Pulmonary Support at ICU Admission*HFOV N (%)3 (50%)20 (11.9%)Nitric Oxide N (%)6 (100%)23 (13.7%)Prone Ventilation N (%)2 (33%)5 (3%)Corticosteroids N (%)2 (33%)85 (50.6%)Neuromuscular Blockade \>24h N (%)6 (100%)47 (30%)Data are presented as mean (SD) or median \[IQR\] unless indicated otherwiseAbbreviations: ECLS = Extracorporeal Lung Support; BMI = Body Mass Index; APACHE = Acute Physiology and Chronic Health Evaluation II Score; HFOV = High Frequency Oscillatory Ventilation; PEEP = Positive End Expiratory Pressure; AST = aspartate aminotransferase Table 2ECLS patient characteristicsPatient CharacteristicsDuration from intubation to start ECLS (d)5 (2.5 - 8.3)Duration on ECLS (d)15 (14 -- 15)Time from end ECLS to extubation (d)17 (13.5-20.5)Pts who had barotrauma before ECLS (n)4 (66%)Pts who had cardiac arrest (n)2 (33%)\*Duration of FiO~2~ = 1.0 before ECLS (h)28.3 (10.5 -- 33.6)v-vECMO (n)4 (67%)ILA (Novalung) (n)2 (33%)RBC transfused (units)7.5 \[6.3 -- 13\]FFP transfused (units)2 \[0 -- 4\]Platelets (adult units)1 \[1 -- 3\]Data are presented as mean (SD) or median \[IQR\]. \* Both cardiac arrests occurred during the period of conventional support prior to initiation of ECLSAbbreviations: ECLS = Extracorporeal Lung Support; ILA = Interventional Lung Assist; RBC = Red Blood Cells; FFP = Fresh Frozen Plasma (1 unit = approximately 250 ml; platelets -- 1 adult unit = 5 pooled random donor platelet units)

Conduct of ECLS {#Sec4}
---------------

Transesophageal or transthoracic echocardiography was performed in all patients who were treated with ECLS. No intracardiac shunts or valvular lesions were discovered. Left ventricular function was normal in all patients; one patient who had previous Tetralogy of Fallot repair had mildly impaired right ventricular function. Right ventricular systolic pressure was normal in three patients, mildly elevated in one patient, and significantly elevated in the remaining two patients. All patients were cannulated peripherally, and all circuits were heparin-coated. For three patients who were treated with vv-ECMO, the circuit utilized a Rotaflow pump and a Quadrox D oxygenator (Maquet-Dynamed, Markham, ON, Canada). For the fourth patient, the circuit consisted of a Biomedicus (Medtronic Inc, Minneapolis, MN, USA) and Medos 2400LT oxygenator. Cannulation for ECMO consisted of drainage from a femoral vein with return to the contralateral femoral vein via a long single stage cannula advanced to the level of the inferior vena cava/right atrial junction. To improve blood flow, three patients required insertion of a third cannula in the right internal jugular vein. Two patients were supported with the Interventional Lung Assist (iLA, NovaLung GmbH, Talheim, Germany). This device does not employ a pump in the circuit. Cannulae are inserted in the femoral artery and vein, and blood flow is driven across the device by the arterial-venous pressure difference.

Extracorporeal lung support was conducted in four ICUs. Three (50%) patients were transferred from one ICU to another to facilitate ECLS. One-half of the ICUs had formal ECLS protocols specifying inclusion/exclusion criteria as well as initiation and monitoring of laboratory and hemodynamic factors. In one-half of the ICUs, a bedside perfusionist was present at all times. In the other half, ECLS was managed by the ICU team with perfusionist support. Additional staffing was required in two ICUs, although there were no bed closures to facilitate ECLS. There were formal targets for platelet levels (median threshold for transfusion 80 x 10^3^·mL^−1^ \[80-120\]) in 75% of the ICUs; the fibrinogen target was 1-2 g·L^−1^ in three ICUs. While on ECLS, a mean of 7.5 (6.3 - 13) units of red blood cells, only two (0 - 4) units of frozen plasma, and one (1 - 3) unit of platelets were transfused per patient (Table [2](#Tab2){ref-type="table"}).

Three patients were supported with HFOV before initiation of ECLS, and one patient was maintained on this mode of ventilation after initiation of ECLS. One-half of the patients required inotropic support while on ECLS, although the use of nitric oxide diminished in frequency. The F~[i]{.smallcaps}~O~2~ delivered by the ventilator was decreased after initiation of ECLS, as was peak airway pressure and positive end expiratory pressure (PEEP). These settings are summarized in Table [3](#Tab3){ref-type="table"}.Table 3ECLS specific characteristics over the course of ECLSCharacteristics of Patients on ECLS\*1 hour before ECLS start2 hours after ECLS start2 days after ECLS start24 hours before ECLS stop48 hours after ECLS stoppH7.31 (0.05)7.43 (0.06)7.40 (0.06)7.41 (0.06)7.39 (0.07)PaO~2~ (mm Hg)58 (17)57 (14)66 (12)105 (45)77 (16)SaO~2~ (%)86 (7)89 (4)92 (4)96 (4.5)94 (5)SvO~2~ (%)85 (7)89 (2)87 (4)83 (12)93 (0)\*FiO~2~1 \[1-1\]0.68 \[0.25\]0.68 \[0.26\]0.59 \[0.22\]0.42 \[0.06\]PEEP (cm H~2~O)20 (0)15 (4)15 (6)14 (6.4)10 (2.8)Ppeak (cm H~2~O)44 (42)34 (4)31 (3)34 (14)27 (3)*Ventilation Mode*Assist-control (pressure)1 (17%)3 (59%)4 (67%)1 (17%)2 (40%)Assist-control (volume)2 (33%)1 (17%)-3 (50%)-Pressure Support\--1 (17%)1 (17%)3 (60%)HFOV3 (50%)1 (17%)1 (17%)\--APRV\-\--1 (17%)-Nitric Oxide, N (%)4 (67%)4 (67%)3 (50%)2 (33%)0 (0%)Neuromuscular blockade, N (%)5 (83%)6 (100%)6 (100%)3 (50%)0 (0%)Inotrope, N (%)2 (33%)3 (50%)3 (50%)3 (50%)1 (20%)MAP (mmHg)83 (16)87 (16)87 (18)76 (22)82 (19)HR (beats/minute)96 (30)99 (26)100 (14)105 (18)116 (19)Cumulative fluid balance (ml)-−185 \[−703 - 491\]105 \[−2007 - 1912\]1338 \[−694 - 2680\]−48 \[−1008 - 1144\]RASS−5 \[−5 - −5\]−5 \[−5 - −5\]−5 \[−5 - −3\]−4 \[−4 - −2\]−2 \[−3 - −1\]Lactate (mmol/L)1.3 (0.2)1.9 (0.6)1.5 (0.3)1.2 (0.6)1.1 (0.4)Platelets (x10^3^/mL)167 \[139-224\]350 \[301-372\]143 \[128-300\]145 \[131 to 168\]159 \[136-190\]ACT (sec)78 (104)213 (65)164 (328)197 (50)-\* APRV = Airway Pressure Release Ventilation; ACT = Activated Clotting Time; RASS = Richmond Agitation Sedation Score; MAP = Mean Arterial Pressure; HR = Heart Rate; HFOV = High Frequency Oscillatory Ventilation; PEEP = Positive End Expiratory Pressure; Ppeak = Peak Airway Pressure; data are means (SD) or median \[IQR\] unless indicated otherwise

Liberation from ECLS {#Sec5}
--------------------

Over the course of ECLS treatment, there was an improvement in PaO~2~/F~[i]{.smallcaps}~O~2~ ratio and a reduction in PaCO~2~ (Figure [1](#Fig1){ref-type="fig"}). Determination of readiness for liberation from ECLS was achieved through a variable combination of assessments for satisfactory negative fluid balance and reduction in the level of supplementary oxygen and ventilatory support (for example, PEEP threshold 12 \[range 10-14\]; F~[i]{.smallcaps}~O~2~ threshold 0.50 \[range 0.50-0.60\]; PCO~2~ threshold 60 \[range 54-70\]). Trials of weaning were performed by reducing F~[i]{.smallcaps}~O~2~ and extracorporeal flow rates. It is difficult to manipulate blood flow for weaning the iLA, so trials of weaning were performed by reducing the gas (sweep) flow.Fig. 1PaO~2~/F~[i]{.smallcaps}~O~2~ ratio and PaCO~2~ (mmHg) over the time course of extracorporeal lung support (ECLS)

Complications {#Sec6}
-------------

There were six oxygenator/membrane exchanges in four patients, all due to clotting of various circuit components. Four exchanges occurred in the two patients supported with iLA, the remaining two were in the patients on vv-ECMO. Three patients had cannula or flow difficulties at various times. Significant air in the oxygenator was discovered in one patient. Pulmonary hemorrhage occurred in one patient, and hemothorax occurred in another patient; both required adjustment of the anticoagulation level. Venous thromboembolism occurred in one patient, and one patient who was supported with vv-ECMO developed heparin-induced thrombocytopenia and was reassigned to a non-heparin coated circuit. Bacteremia occurred in three patients. Although there was no commonly employed protocol for monitoring for hemolysis and liver dysfunction, hyperbilirubinemia and increased liver enzymes occurred in three patients. Two patients received renal replacement therapy. Four patients developed pneumothoraces, three while on ECLS with one requiring a thoracostomy tube for bronchopleural fistula management.

Outcomes {#Sec7}
--------

Four patients were successfully liberated from ECLS with acceptable gas exchange and hemodynamics 48 hr after liberation. However these patients required an additional 17 (13.5-20.5) days of conventional mechanical ventilation. The total duration of mechanical ventilation, ICU length of stay, and hospital length of stay was longer in the ECLS group than in the non-ECLS group. Two ECLS patients died (33% mortality *vs* 17.3% for the whole cohort) of multisystem organ failure while on ECLS. The first patient who was 17 yr of age died after 21 days of ventilation and 15 days of ECLS; the second patient was 51 yr of age and died after 16 days of ventilation and 14 days of ECLS. These outcomes are summarized in Table [4](#Tab4){ref-type="table"}.Table 4Outcomes of ECLS patients compared to the entire cohort[@CR10]OutcomesECLS (n = 6)All patients (n = 168)[@CR10]Mortality at 28 days from ICU Admission (n)2 (33%)24 (14.3%)Duration of Ventilation (d)26.5 \[18 - 40.3\]12 \[6 -- 20\]From Hospitalization to Death (d)18 \[15 -- 21\]14 \[6 -- 20\]Length of ICU stay (d)28 \[18.5 - 37.5\]12 \[5 -- 20\]Data are presented as median \[IQR\] unless otherwise indicated

Discussion {#Sec8}
==========

Six of the 168 patients who had confirmed H1N1-2009 infection in Canada were deemed to be unresponsive to conventional therapeutic interventions and were treated with ECLS. Four of these patients were successfully liberated from ECLS and survived their critical illness. Notably, this outbreak disproportionately affected young females, Aboriginal patients, and those who did not have major pre-existing comorbidities.

At present, ECLS for ARDS is generally considered as an alternative treatment in adults with ARDS who are unresponsive to other forms of support. At present, there is no consensus on absolute indications or contra-indications to ECMO or iLA. Initiation guidelines vary among centres and are based mostly on personal and institutional experience. As the H1N1-2009 pandemic evolved, however, ECLS teams received requests for this therapy. The many uncertain aspects of the pandemic further clouded the decision-making process. Specifically, the course of the disease was uncertain, as was the number of potentially affected individuals. Nonetheless, as more patients developed ARDS due to H1N1-2009 infection, it became clear that an attempt at ECLS would be required in some young, otherwise healthy individuals.

The greatest benefit of ECMO is expected to occur when initiated early in the course of severe lung injury before the evolution of increasing multisystem disease. However, it is challenging to identify patients who will not respond to more conventional therapies. Numerous studies have shown that ECMO is not beneficial and may be associated with increased mortality if offered to *all* patients who have ARDS according to the consensus criteria.[@CR20] In 1979, the first randomized trial comparing ECMO with conventional ventilation for treatment of ARDS reported a survival rate of \< 10% in both groups and no significant difference in mortality.[@CR21] However, there has been recent interest in non-randomized studies supporting the use of ECMO in adults who have severe hypoxic respiratory failure.[@CR22]

Most recently, the Conventional Ventilation or ECMO for Severe Adult Respiratory Failure (CESAR) trial compared ARDS treatment with or without ECMO in patients who had very severe ARDS. In this study, 180 patients were prospectively randomized to treatment in centres that deliver ECMO or to treatment in centres that deliver conventional ventilation.[@CR19] While the investigators were able to demonstrate an improvement in the composite outcome of death/cognitive dysfunction in favour of ECMO, there was no difference in all-cause mortality.[@CR23] Furthermore, although these were patients with severe ARDS, ECMO was not the sole therapy in that treatment arm. With proper patient selection, the mortality among patients who have the most severely impaired gas exchange treated with ECMO can be lowered to approximate the mortality of those patients not requiring ECMO.[@CR24]-[@CR28] The Australia and New Zealand (ANZ) influenza investigators recently reported their experience with ECMO for respiratory failure secondary to H1N1-2009 infection in ANZ.[@CR29] In this series, ECMO usage for H1N1-2009 infection was frequent (68/201, 33.8%), whereas it was infrequent in Canada (6/168, 3.6%). The time from intubation to initiation of ECLS in ANZ was also shorter, i.e., mean two days *vs* mean five days in our series, although gas exchange parameters immediately prior to the initiation of ECLS were similar. The sole method of ECLS used in the ANZ series was vv-ECMO. Survival rates in both series were similar.

While ECMO has been in use in Canada for over 20 yr, the Novalung iLA is a new device to Canada, approved in 2008, and has been used in very few centres. Proposed as an alternative to the full ECMO, the pumpless iLA circuit has demonstrated benefit in severe hypoxemic lung failure (PaO~2~/F~[i]{.smallcaps}~O~2~ ratio \< 65 despite optimized ventilator settings).[@CR30] Although this device is most beneficial for carbon dioxide removal, it may also improve oxygenation. The indications for iLA have therefore been extended by some to include the prevention of ventilator-associated lung injury during the early phase of ARDS.[@CR13] This concept recognizes the inability to limit plateau pressures and tidal volumes in a situation of grossly diminished respiratory compliance without causing severe hypercapnia and profound respiratory acidosis. However, there are no published clinical trials regarding this device. The Canadian critically ill H1N1 patients were characterized by a hyperacute disease process and rapid deterioration, often within hours of hospital admission. Our limited experience of iLA for H1N1-infection cannot determine whether this treatment is effective. The results from a multicentre trial (XTRAVENT, Clinical.Trials.Gov. identifier NCT00538928) may provide further insight into the utility of this therapy. As such, iLA therapy should be considered experimental at the present time, and treatment should be offered in the context of clinical investigation.

Traditionally, the conduct of ECMO has required constant attention from a perfusionist who is present at the bedside. In our series, only one-half of the ICUs mandated "in-house" coverage by perfusion staff. The rationale for mandating constant attendance by perfusion staff was to deal with the unlikely scenario of a circuit catastrophe, such as inadvertent decannulation, air embolism, or clotting of the circuit. Circuit complications were quite frequent in our series (four of six patients required circuit/oxygenator exchange), including two patients where ECMO specialists did not constantly supervise ECLS. Despite the practices that we observed, the general consensus is that ECLS specialists should remain in the hospital when a patient is undergoing ECLS.[@CR22]

In conclusion, the use of ECLS in the setting of H1N1-2009 infection is feasible and may be effective in certain centres. The use of ECMO and perhaps iLA may support gas exchange and prevent on-going lung injury and mortality in patients who have severe injury that is refractory to other interventions. However, this treatment is associated with a high incidence of serious complications. Therefore, jurisdictions should develop guidelines for consideration of this therapy for the expected autumn and winter wave of influenza A (H1N1) 2009.

This article is accompanied by an editorial. Please see Can J Anesth 2010; 57(3).
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